MetiMedi, a bio pharmaceutical company based in South Korea, is at the forefront of cutting-edge research in immuno-oncology. The company is committed to developing a unique platform technology that addresses the unmet needs of solid cancer therapies and beyond. By targeting specific cellular metabolic reprogramming in tumor cells, MetiMedi's immunotherapy leads to tumor necroptosis and immune activation, with exceptional safety. Phase 2 clinical studies with METI-101 for refractory metastatic colorectal cancer have demonstrated efficacy and safety.
Company Details
- Employees
- 6
- Founded
- -
- Address
- Imi-Ro 40, Uiwang-Si,gyeonggi-Do 16006,korea, Republic Of
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.metimedi.com
- HQ
- Uiwang-si, Gyeonggi-do
Metimedi Co., Ltd. Questions
Metimedi Co., Ltd.'s website is http://www.metimedi.com
Metimedi Co., Ltd.'s LinkedIn profile is https://kr.linkedin.com/company/metimedi
Metimedi Co., Ltd. has
6 employees.
View email and phone details for 6
employees at Metimedi Co., Ltd..
Metimedi Co., Ltd.'s industry is
Biotechnology Research
Metimedi Co., Ltd.'s top competitors are
St Innovative Diagnostics Ltd.,
Haimbio,
Seal Biosciences,
Cmg Pharmaceutical,
Recerise Therapeutics,
Spark Biopharma, Inc.,
G+flas Life Sciences, Inc.,
Gi Cell (지아이셀),
Amtixbio,
Synchrony.
Metimedi Co., Ltd.'s categories are Biotechnology Research
Metimedi Co., Ltd.'s founding year is 2016
